Geriatric Specialty Recertification Literature Study: Module 1A-B (L259073)

ACPE Numbers: Various – see listing below
Content Release Date: July 16, 2025
Expiration Dates: July 14, 2026
Activity Type: Application-based
CE Credits: 10 hours (BPS and ACPE)
Activity Fee: $65 (ASHP member); $120 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Module 1A: Cardiovascular - This module focuses on cardiovascular issues, including apixiban for stroke prevention, a meta-analysis of shorter antiplatelet therapy in PCI, beta blockers after MI, and tenecteplase for stroke without thrombectomy.

Module 1B: General Geriatrics - This module focuses on general geriatric issues including dupilumab for COPD, fall prevention, RSV vaccine, and resmetirom in NASH.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCGP recertification approved by the BPS.

Accreditation

Target Audience

Recertification Credit

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ASHP and ACCP are approved by BPS as providers for the recertification of BCGP.

Learning Activity	ACPE Number	Contact Hours (ACPE and BPS)	Assessment Pass Point
Module 1A: Cardiovascular	0204-9999-25-922-H01-P	5.0	75%
Module 1B: General Geriatrics	0204-9999-25-923-H01-P	5.0	72%

Articles and Learning Objectives

Module 1A: Cardiovascular
0204-9999-25-922-H01-P

This module focuses on cardiovascular issues, including apixiban for stroke prevention, a meta-analysis of shorter antiplatelet therapy in PCI, beta blockers after MI, and tenecteplase for stroke without thrombectomy.

Healey JS, Lopes RD, Granger CB, et al; ARTESIA Investigators. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med. 2024 Jan 11;390(2):107-117. doi: 10.1056/NEJMoa2310234. Epub 2023 Nov 12.

Describe the Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Subclinical Atrial Fibrillation (ARTESIA) study by Healey and colleagues.
Develop recommendations for the use of apixaban for stroke prevention in patients with subclinical atrial fibrillation who are at increased risk for stroke.

Park DY, Hu JR, Jamil Y, Kelsey MD, Jones WS, Frampton J, Kochar A, Aronow WS, Damluji AA, Nanna MG. Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024

Describe the systematic review and network meta-analysis by Park and colleagues of studies of the duration of dual antiplatelet therapy (DAPT) in older adults after percutaneous coronary intervention (PCI).
Develop recommendations for the duration of dual antiplatelet therapy (DAPT) in older adults after percutaneous coronary intervention (PCI).

T. Yndigegn, B. Lindahl, K. Mars, J. Alfredsson, J. Benatar, L. Brandin, D. Erlinge, O. Hallen, C. Held, P. Hjalmarsson, P. Johansson, P. Karlström, T. Kellerth, T. Marandi, A. Ravn-Fischer, J. Sundström, O. Östlund, R. Hofmann, and T. Jernberg, for the REDUCE-AMI

Describe the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) by Yndigegn and colleagues.
Develop recommendations for the use of beta-blockers in patients with acute myocardial infarction and a preserved ejection fraction.

Xiong Y, Campbell BCV, Schwamm LH, et al; TRACE-III Investigators. Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy. N Engl J Med. 2024 Jul 18;391(3):203-212. doi: 10.1056/NEJMoa2402980. Epub 2024 Jun 14.

Describe the Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III (TRACE-III) trial by Xiong and colleagues.
Develop recommendations for the use of tenecteplase in patients with acute ischemic stroke.

Module 1B: General Geriatrics
0204-9999-25-923-H01-P

This module focuses on general geriatric issues including dupilumab for COPD, fall prevention, RSV vaccine, and resmetirom in NASH.

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB; NOTUS Study Investigators.

Describe the NOTUS study by Bhatt and colleagues of dupilumab for patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who are at an increased risk of exacerbation.
Develop recommendations for the use of dupilumab for patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who are at an increased risk of exacerbation.

Guirguis-Blake JM, Perdue LA, Coppola EL, Bean SI. Interventions to Prevent Falls in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2024 Jul 2;332(1):58-69. doi: 10.1001/jama.2024.4166.

Describe the US Preventive Services Task Force (USPSTF) updated evidence report and systematic review of interventions to prevent falls in older adults.
Develop recommendations for interventions to prevent falls in community-dwelling older adults.

Britton A, Roper LE, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702.

Summarize the 2024 updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for the use of respiratory syncytial virus (RSV) vaccines in adults aged ≥60 years.
Develop recommendations for the use of respiratory syncytial virus (RSV) vaccines in adults aged ≥60 years.

Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.

Describe the MAESTRO-NASH study by Harrison and colleagues of resmetirom for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Develop recommendations for the use of resmetirom in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Faculty

Full Faculty Bios

Teresa DeLellis, PharmD, BCPS, BCGP, AGSF
Chair and Associate Professor of Pharmacy Practice
Manchester University
Fort Wayne, Indiana

Julianna Fernandez, PharmD, BCPS, BCGP
Clinical Associate Professor and Vice Chair of Pharmacy Practice and Translational Research
University of Houston
Houston, Texas

Zach Klick, PharmD, BCPS, BCACP, BCCP, CPP
Cardiology Pharmacist/PGY2 Cardiology RPD
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina

Sum Lam, PharmD, BCGP, BCPS
Clinical Professor
St. John's University
Queens, New York

Nevena Mihalovich, PharmD, BCCP, BCPS
Cardiology Clinical Pharmacist
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina

Dana Carroll, PharmD, BCGP, BCPS, CDES*
Clinical Professor
Auburn University Harrison School of Pharmacy
University of Alabama Family Medicine
Tuscaloosa, Alabama

Lisa Hutchison, PharmD, MPH, BCGP, BCPS*
Professor and Vice Chair
University of Arkansas for Medical Sciences College of Pharmacy
Little Rock, Arkansas

Maria Shin, PharmD, BCGP, BCPS*
Clinical Pharmacy Specialist in Internal Medicine
Robley Rex Louisville Veterans Affairs Medical Center
Louisville, Kentucky

*Content Matter Experts

Reviewers

Field Testers

Ramadas Balasubramanian, PharmD, PhD, BCGP, BCACP, FASCP
Michae Barton, PharmD, BCGP, BCPS
Jennifer Berrigan, PharmD, BCGP
Donna Breese, PharmD, BCGP
Emily Brueggemann, PharmD, BCGP
Tina Caliendo, PharmD, BCGP, BCACP
Anshu Chen, BSPharm, PhD, BCGP
Kate Cozart, MEd, PharmD, BCPS, BCGP, BCACP
Marjan Doostan, Pharm D, BCGP
Brian Doss, PharmD, BCGP
Torri Fuller, PharmD, BCGP
Luke Gittings, PharmD, BCGP
Samantha Kaeberlein, PharmD, BCGP
Megan Kaiser, PharmD, BCPS, BCGP
Nancy Laux, PharmD, BCPS, BCGP
Amanda Lovell, PharmD, BCGP
Bindu Mathews, PharmD, BCGP
Shingayi Molai, PharmD
Malcolm Nasirah, PharmD, BCGP
Sarah Norman, PharmD, BCPS, BCPP, BCGP
Susan Pfoertner, BS Pharm, PharmD, BCGP
Bridget Protus, PharmD, BCPS
Carly Ranson, PharmD, BCGP
Mohammad Rattu, PharmD, BCOP, BCPS, BCGP
Jocelyn Reynoso, PharmD, BCPS, BCGP, BCSCP
Ariane Ruelas, PharmD, BCGP, BCPS
Elise Shepard, PharmD, BCGP
Sydney Springer, PharmD, MS, BCGP
Stephanie Stewart, PharmD, MBA, BCGP
Tracee Strout, PharmD, BCPS, BCGP
Molly Tice, PharmD, BCGP
Maggie Victorin, PharmD, BCGP, CPh
Paul Wong, PharmD, BCGP, BCPS
Christine Wu, PharmD, BCPS, BCGP

Relevant Financial Relationship Disclosures

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

All persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.